Tranexamic Acid in Early Treatment of Intracerebral Hemorrhage

It appears to be safe, but this small study showed no benefit in outcomes.

At present, no specific pharmacologic treatment has been demonstrated to improve outcomes in patients with intracerebral hemorrhage (ICH). Various hemostatic agents have been tested without definite proof of efficacy. In a randomized, placebo-controlled trial, these investigators tested off-label use of tranexamic acid (TXA) in 100 patients with ICH (median age, 71) who could be treated within 4.5 hours of symptom onset and who had a “spot sign” on computed tomography with contrast, which is suggestive of elevated risk for hematoma expansion.

TXA or placebo was given intravenously at 1 g over 10 minutes, followed by infusion of 1 g over 8 hours. Patients with very large hematomas (>70 mL) or impaired consciousness were excluded. The primary …

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Tranexamic Acid in Early Treatment of Intracerebral Hemorrhage

Topics

Reviewing Author